BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile

Reuters01-05

MetaVia Inc MTVA.O:

METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILE
METAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDY
METAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDY
METAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDY
METAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDY

Source text: ID:nPn6Kvghwa

Further company coverage: MTVA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601882112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601882112","market":"us","top_or_hot":-1,"title":"BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile</title></head><body><p><a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a> <span>MTVA.O</span>:</p><ul><li><p>METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILE</p></li><li><p>METAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDY</p></li><li><p>METAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDY</p></li><li><p>METAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDY</p></li><li><p>METAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDY</p></li></ul><p>Source text: <span>ID:nPn6Kvghwa</span></p><p>Further company coverage: <span>MTVA.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile</title></head><body><p><a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a> <span>MTVA.O</span>:</p><ul><li><p>METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILE</p></li><li><p>METAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDY</p></li><li><p>METAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDY</p></li><li><p>METAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDY</p></li><li><p>METAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDY</p></li></ul><p>Source text: <span>ID:nPn6Kvghwa</span></p><p>Further company coverage: <span>MTVA.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTVA","symbol_name":"MetaVia Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA1CYWC6:1","article_id":"2601882112","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601882112","pubTimestamp":1767622182,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic E","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MTVA":"MetaVia Inc","BK4139":"生物科技"},"translate_title":"简介-Metavia报告了Da-1726治疗代谢疾病的1B期临床试验的具有统计学意义的积极结果-证明了强烈的血糖反应、显着的直接肝脏效应、强劲的体重减轻和良好的安全性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety ProfileMetaVia Inc MTVA.O:METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILEMETAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDYMETAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDYMETAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDYMETAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDYSource text: ID:nPn6KvghwaFurther company coverage: MTVA.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601882112","isCrawlerRequest":true}